Comparative Pharmacology
Head-to-head clinical analysis: AZACITIDINE versus VIDAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZACITIDINE versus VIDAZA.
AZACITIDINE vs VIDAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA methyltransferase, leading to hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in bone marrow. It incorporates into RNA and DNA, causing disruption of nucleic acid metabolism and apoptosis.
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA methyltransferase, causing hypomethylation of DNA and direct cytotoxicity in abnormal hematopoietic cells.
75 mg/m² subcutaneously or intravenously once daily for 7 days every 28 days.
75 mg/m2 subcutaneously or intravenously once daily for 7 days every 4 weeks.
None Documented
None Documented
Clinical Note
moderateAzacitidine + Digoxin
"Azacitidine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAzacitidine + Digitoxin
"Azacitidine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAzacitidine + Deslanoside
"Azacitidine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAzacitidine + Acetyldigitoxin
"Azacitidine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 4 hours (subcutaneous or intravenous); reflects rapid deamination by cytidine deaminase.
Terminal half-life: 5-7 hours (subcutaneous); 3-5 hours (intravenous); supports 7-day dosing cycle
Renal (primarily as metabolites, ~50-85% of administered dose within 72 hours); fecal/biliary negligible.
Renal: 50-85% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Category C
Category C
Hypomethylating Agent
Hypomethylating Agent